|Bid price||16.00||Open price||16.20|
|Ask price||17.50||Prev close||16.25|
Register now for FREE live Proteome Sciences share prices, Proteome Sciences stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get Proteome Sciences Level 2 Data, indepth research tools and investor commentary for Proteome Sciences (PRM) and other London Stock Exchange equities.
Register now for FREE Proteome Sciences share price charts
|Sector||Pharmaceuticals & Biotechnology||ISIN||GB0003104196|
|Activites||Proteome Sciences plc applies high sensitivity proteomics to identify and characterise differential protein expression in diseases for diagnostic, prognostic and therapeutic applications. It has to date developed sensitive blood assays for stroke, vCJD, BSE, solid organ transplant rejection and Alzheimer's disease. The main focus of its research currently addresses neurological, neurodegenerative, diabetes/obesity, oncology and cardiovascular conditions. In addition to its own proprietary biomarkers, Proteome Sciences has developed ProteoShop Â® (Proteome Sciences High Output Proteomics), a tool box that offers high sensitivity and high throughput gel and gel-free proprietary technologies for the identification of potential biomarkers and drug targets. These include specialisation in membrane proteins and protein phosphorylation. The Company has developed a range of specialist reagents to improve the performance and quantitation of protein separation and characterisation with mass spectrometry, bioinformatics, statistics and pattern recognition. These include Sensitizer Â®, PST Â®, qPST Â® and TMT Â®. Commercialisation is being actively pursued across the portfolio of the Company's programmes and technologies with licensing deals signed in biomarkers for Stroke and TSEs and for ProteoSHOP Â®.||Index||n/a|
|Latest Share Price (p)||16.75||Net Gearing (%)||88.06|
|Market Capitalisation (£m)||34.79||Gross Gearing (%)||110.60|
|Shares in issue (m)||214.11||Debt Ratio||-55.30|
|P/E Ratio||-9.62||Debt-to-Equity Ratio||0.03|
|Total dividends per share (p)||0.00||Assets / Equity Ratio||-9.43|
|Dividend Yield (%)||0.00||Price to book value||-39.53|
|Dividend cover (x)||0.00||ROCE (%)||742.11|
|Earning per share (p)||-1.69||EPS Growth (%)||-4.32|
|52 week high / low||30.00 / 15.25||DPS Growth (%)||n/a|
|Dec.Date||Type||Director||Pos||No. of Shares|
|06/07/2010||PLAC||R Steve Harris||RES||24,199|
|06/07/2010||PLAC||Prof William Dawson||NED||5,248|
Story provided by StockMarketWire.com
/* */ RNS Number : 6056E Proteome Sciences PLC 05 November 2015 PRESS RELEASE CK1d inhibitors reduce Alzheimer's tau phosphorylation 5 November 2015 - Cobham, UK From the 8 th...
Register now for FREE Proteome Sciences company news
Does anyone have an opinion on PRM. No comparable news for a while. Price seems to be sliding once again.
The price has fallen quite significantly over recent weeks then they bring out todays statement. Other statements have said the fundamentals haven't changed. Its not all doom and gloom but we will be waitng much longer for progress to be made. What do you think?
WELL INFORMED CITY SOURCE REVEALED IMPORTANT MEETING TOOK PLACE WITHIN LAST WEEK AND A MAJOR DEAL WILL BE ANNOUNCED WITHIN DAYS.THE SHARES WILL BE RE-RATED SUBSTANTIALLY FOLLOWING THE ANNOUNCEMENT.
Register now for FREE Proteome Sciences share price discussions